ASA bans Eucerin ad claiming skin rejuvenation after citing misleading claims.

Britain's advertising watchdog has ordered the immediate removal of a high-profile billboard for Eucerin Hyaluron-Filler Epigenetic Serum, citing 'misleading' assertions that the product could make users appear up to five years younger. The advertisement, which was displayed at Balham London Underground station last year and priced as high as £49 at Boots, featured bold claims of 'clinically proven' skin rejuvenation based on a trial involving 160 participants over a four-week period.

Despite the manufacturer, Beiersdorf, arguing that the 'up to' phrasing indicated a maximum potential rather than a guaranteed result, and insisting that all their products are backed by scientific research, the Advertising Standards Authority (ASA) found the evidence insufficient. The probe revealed critical flaws in the study's methodology, noting that the trial was conducted in a significantly hotter, sunnier climate than the United Kingdom and involved participants with different skin characteristics. Consequently, the ASA ruled that the findings could not be applied to the British market.

Further scrutiny exposed the absence of a control group and a lack of transparency regarding how study participants were recruited. The ASA emphasized that while they reviewed four studies and a peer-reviewed paper, none provided robust evidence to substantiate the claim of a five-year visual age reduction. The research relied heavily on self-reported opinions rather than official measurements, and additional data suggested only a one-year reduction in biological skin age. Furthermore, one cited study examined only the active ingredient rather than the final serum product.

In a decisive move to protect consumers from unsubstantiated promises, the ASA concluded that the claim was misleading and issued a strict directive: the advertisement must not appear again in the complained-of form. Beiersdorf confirmed that the billboard is no longer on display in the UK and has fully cooperated with the ruling. While the company maintains confidence in its global scientific evidence and commitment to industry standards, they have agreed to cease implying such specific age-reduction benefits for this product within the UK until robust, applicable evidence is presented. This ruling underscores the vital role of regulatory oversight in ensuring that public health claims are grounded in reality rather than marketing speculation.